MetaCap

Acumen Pharmaceuticals (ABOS) vs Pluri (PLUR)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Pluri (PLUR) has outperformed Acumen Pharmaceuticals (ABOS) over the past year, losing 75.3% versus a loss of 88.1%. Over five years, PLUR leads with a -95.6% price change compared with -97.7% for ABOS. Pluri is the larger company by market cap ($13.5 million vs $13.5 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ABOS-88.12%PLUR-75.26%
+125%+13%-98%
Nov 21, 20251 yearNov 20, 2026
ABOS-98.11%PLUR-95.53%
+7%-48%-103%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ABOS versus PLUR key metrics
MetricABOSPLUR
Share price$0.1865$0.94
Market cap$13.49M$13.51M
1-day change-3.52%-3.07%
YTD return-91.16%-68.56%
1-year return-88.12%-75.26%
5-year return-97.74%-95.63%
EPS (TTM)$-1.55$-2.65
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$1.02M
Revenue growth (YoY)—-23.95%
Net income (latest FY)$-121.33M$-23.82M
Gross margin—44.59%
Operating margin—-2454.53%
Net margin—-2344.59%
52-week high$3.60$3.94
52-week low$0.16$0.85
Distance from 52-week high-94.82%-76.14%
Analyst consensusstrong_buy—
Avg. price target upside+3975.07%—
Average volume2.73M36.98K
Shares outstanding72.33M14.38M
Employees6092
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • PLUR has outperformed ABOS by 12.9 percentage points over the past year.

About Acumen Pharmaceuticals

ABOS stock →

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer's disease. It focuses on advancing a targeted immunotherapy drug candidate, sabirnetug (ACU193), which is in its Phase 2 ALTITUDE-AD clinical trial to target toxic soluble amyloid beta oligomers.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 60 employees

About Pluri

PLUR stock →

Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and related technologies for various industries. The company develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and an immunotherapy platform.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 92 employees

ABOS vs PLUR FAQ

Which is bigger, Acumen Pharmaceuticals or Pluri?

Pluri (PLUR) is larger, with a market capitalization of $13.51M compared with $13.49M for Acumen Pharmaceuticals (ABOS).

Which stock has performed better over the past year, ABOS or PLUR?

PLUR returned -75.26% over the past 12 months, compared with -88.12% for ABOS (price return, excluding dividends). Past performance does not predict future results.

Are Acumen Pharmaceuticals and Pluri in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons